FERRARI, GIULIANA
 Distribuzione geografica
Continente #
EU - Europa 674
NA - Nord America 469
AS - Asia 312
SA - Sud America 4
AF - Africa 3
OC - Oceania 3
Totale 1.465
Nazione #
US - Stati Uniti d'America 465
SE - Svezia 416
CN - Cina 155
SG - Singapore 122
RU - Federazione Russa 96
IT - Italia 79
FI - Finlandia 23
DE - Germania 20
IE - Irlanda 19
IN - India 13
GB - Regno Unito 7
JP - Giappone 7
FR - Francia 4
AU - Australia 3
CA - Canada 3
ES - Italia 3
ET - Etiopia 3
PE - Perù 3
TR - Turchia 3
CH - Svizzera 2
HK - Hong Kong 2
KG - Kirghizistan 2
MY - Malesia 2
NL - Olanda 2
AM - Armenia 1
BD - Bangladesh 1
BE - Belgio 1
EC - Ecuador 1
ID - Indonesia 1
KZ - Kazakistan 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
UA - Ucraina 1
VN - Vietnam 1
Totale 1.465
Città #
Lawrence 112
Princeton 112
Ashburn 99
Shanghai 80
Singapore 79
Milan 45
Moscow 45
Boardman 25
Helsinki 22
Dublin 19
New York 17
Guangzhou 12
Pune 12
Xi'an 8
Los Angeles 6
Seattle 5
Turin 5
Wuxi 5
Beijing 4
Shenzhen 4
Washington 4
Aksum 3
Ankara 3
Barcelona 3
Borås 3
Hanover 3
Lima 3
Plymouth 3
Bishkek 2
Dallas 2
Düsseldorf 2
Indianapolis 2
Jiaxing 2
Linfen 2
Monza 2
Pisa 2
Sigmaringendorf 2
Sydney 2
Tokyo 2
Vauderens 2
Vigonza 2
Albuquerque 1
Almaty 1
Altoona 1
Andover 1
Angers 1
Apollo 1
Asti 1
Bogor 1
Cambridge 1
Cernusco sul Naviglio 1
Chieti 1
Conshohocken 1
Da Nang 1
Dalian 1
Dreieich 1
Durham 1
Easley 1
Fort Worth 1
Frankfurt am Main 1
Geislingen an der Steige 1
Hefei 1
Hong Kong 1
Jinhua 1
Kochi 1
Kuala Lumpur 1
Kunshan 1
Lappeenranta 1
London 1
Marikina City 1
Modena 1
Mountain View 1
Naaldwijk 1
Nanping 1
Napoli 1
Newark 1
Old Westbury 1
Pordenone 1
Quanzhou 1
Quito 1
Reston 1
Ronkonkoma 1
Santa Clara 1
Schaarbeek 1
Springfield 1
Stockholm 1
Sunshine Coast 1
Toronto 1
Trieste 1
Upland 1
Weitang 1
Wuhan 1
Yangquan 1
Yerevan 1
Totale 820
Nome #
Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation 37
Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia 24
Correcting b-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity 24
Bone marrow as source of hematopoietic stem cells for human gene therapy of beta thalassemia 23
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia 23
Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to Plerixafor alone 22
Transcription factor binding sites as genetic determinants of retroviral integration in the human genome 21
A clinical protocol for transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA deficient SCID 21
A human PBL immunodeficient mouse model for in vivo preclinical studies of human gene therapy. 21
Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity 21
Bone marrow as an alternative site for islet transplantation 20
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice 20
The EHA Research Roadmap: Hematopoietic Stem Cell Gene Therapy 20
Bone marrow as an alternative site for islet transplantation 19
Gene therapy using haematopoietic stem and progenitor cells 19
A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers 18
Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia 17
Strain polymorphism and tentative mapping of mouse ornithine decarboxylase 17
Aberrant, noninfectious HIV-1 particles are released by chronically infected human T cells transduced with a retroviral vector expressing an interfering HIV-1 variant 17
Bone marrow-derived stem cells repopulate glomerular and tubular kidney components - Effect of hyperglycemia 17
Terapia genica e malattia ereditaria 17
A non-producer interfering HIV-1 provirus can be transduced through a MLV-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus 17
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia 17
Failure to correct murine muscular dystrophy 16
A Highly conserved SOX6 double binding site mediates SOX6 gene downregulation in erythroid cells 16
Bone marrow-derived hematopoietic cells undergo myogenic differentiation following a Pax-7 independent pathway 16
Selective engraftment of genetically modified hematopoietic stem cells by a truncated erythropoietin receptor 16
Characterization of Papilloma virus polypeptides from bovine cutaneous fibropapillomas 16
An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4 16
Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer 15
Muscle regeneration by bone marrow-derived myogenic progenitors 15
Clinical protocol: transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID 15
In vivo and in vitro models for the analysis of retroviral vector mediated expression of human ADA in ADA deficient cells from patients affected by severe combined immunodeficiency. 15
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 15
An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency 15
Clonal analysis of stably transduced human epidermal stem cells in culture 15
T-cell receptor genes in tassel-eared squirrels (Sciurus aberti). I. Genetic polymorhism and divergence in the Abert and Kaibab subspecies 14
Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets 14
Ly-5.185 molecule is associated with thymic maturation of lymphocytes but not with their cytotoxic activity 14
The second transferrin receptor regulates red blood cell production in mice 14
Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement 14
Deletion of a negatively acting sequence in a chimeric GATA-1 enchancer-LTR greatly increases retroviral-mediated erythroid expression 14
Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts 14
Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA- Immunodeficient Patients 14
TRANSFER OF THE HSV-TK GENE INTO DONOR PERIPHERAL-BLOOD LYMPHOCYTES FOR IN-VIVO IMMUNOMODULATION OF DONOR ANTITUMOR IMMUNITY AFTER ALLO-BMT 14
Retroviral heterogeneity in mouse lymphomas 14
Strain specific retroviral sequences are anomalously represented in DNA of mouse lymphomas 14
Unique molecular and functional features of extramedullary hematopoietic stem and progenitor cell reservoirs in humans 13
Transcript imaging of human T helper cell development using oligonucleotide arrays 13
Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement 13
Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells 13
The homeodomain transcription factor Prep1 (pKnox1) is required for hematopoietic stem and progenitor cell activity 13
The GATA1-HS2 Enhancer allows persistent and position-independent expression of ß-globin transgene 13
Persistent and Position Independent Transgene Expression in Erythroid Cells Transduced 13
Transcriptional, epigenetic and retroviral signatures identify regulatory regions involved in hematopoietic lineage commitment 13
Transfer of the ADA gene into human ADA-deficient T Lymphocytes reconstitutes specific immune functions 13
Safety of retroviral gene marking with a truncated NGF receptor 13
Gene Therapy Approaches to Hemoglobinopathies 13
Myogenic conversion of mammalian fibroblasts induced by differentiating muscle cells 13
Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: Evidence from a murine model 13
Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice 13
Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease 13
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells 13
Phosphorylation of synapsin I by cAMP-dependent protein kinase controls synaptic vesicle dynamics in developing neurons. 12
Myogenic stem cells from the bone marrow: a therapeutic alternative for muscular dystrophy? 12
Cotransduction with MGMT and Ubiquitous or Erythroid-Specific GFP Lentiviruses Allows Enrichment of Dual-Positive Hematopoietic Progenitor Cells In Vivo 12
Stem cell plasticity: time for a reappraisal? 12
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo 12
When diagnostics meets translational research: detection of hemoglobin fractions in cellular lysates from in vitro erythroid cultures by Capillarys2 Flex Piercing® analyzer (Sebia) 12
In vivo and in vitro models for analysis of retroviral vector mediated expression of human ADA in ADA deficient cells from patients affected by severe combined immunodeficiency 12
Retroviral vector gene-transfer into donor peripheral-blood lymphocytes for in-vitro selection and in-vivo immunomodulation of donor antitumor immunity after allo-BMT 12
Vector design influences retroviral integration in human hematopoietic cells 12
Gene-transfer into peripheral-blood lymphocytes for in-vivo immunomodulation of donor antitumor immunity in a patient affected by EBV-induced lymphoma 12
Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophy 12
Preclinical Assessment of a Gene Therapy Approach to beta-Thalassemia 12
Gene transfer into human primary myogenic cells. 12
Conditioning Regimens in Long-Term Pre-Clinical Studies to Support Development of Ex Vivo Gene Therapy: Review of Nonproliferative and Proliferative Changes 12
Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy 11
Targeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease 11
Competitive engraftment of hematopoietic stem cells genetically modified with a truncated erythropoietin receptor 11
Correction of ß-thalassemia major by gene transfer in hematopoietic progenitors of pediatric patients 11
Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts 11
Pancreatic islets recruit mesenchymal stem cells by release of chemokines 11
Gene therapy for beta thalassemia: preclinical studies on human cells 11
Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy 11
The influence of vector design on integration site selection by gamma-retroviral and lentiviral vectors 11
Hypomorhic mutation of the TALE gene Prep1 (pKnox1) causes a major reduction of Pbx and Meis proteins and a pleiotropic embryonic phenotype 11
Adenine base editor-mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation 10
Genetic modification of somatic stem cells. The progress, problems and prospects of a new therapeutic technology 10
Report on the 2nd annual meeting of the European Working Group on Human Gene Transfer and Therapy, London, November 18-21, 1994 10
Gene therapy for beta-thalassemia: analysis of therapeutic efficiency in pre-clinical models 10
Transcription Factor Binding Sites Are Genetic Determinant of Retroviral Integration in the Human Genome 10
Terapia Genica 10
Gene therapy and gene editing strategies for hemoglobinopathies 10
Retroviral vectors for human gene therapy 10
Retroviral vectors for human gene therapy 10
Safety of retroviral gene marking with a truncated NGF receptor 9
Reversible Immortalization of Human Myogenic Cells by Site-Specific Excision of a Retrovirally Transferred Oncogene 9
Hot spots of retroviral integration in human CD34+ hematopoietic cells 9
High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies 8
Totale 1.438
Categoria #
all - tutte 31.551
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.551


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 0 1 0 1 0
2020/202112 1 0 0 1 0 7 2 0 1 0 0 0
2021/2022112 0 0 0 43 0 2 1 51 4 5 1 5
2022/2023685 253 169 45 5 2 99 25 52 17 9 6 3
2023/2024369 10 20 30 104 15 45 11 5 0 7 19 103
2024/2025374 218 42 16 62 36 0 0 0 0 0 0 0
Totale 1.592